Literature DB >> 6785306

Comparison of passive hemagglutination, bactericidal activity, and radioimmunological methods in measuring antibody responses to Neisseria meningitidis group A capsular polysaccharide vaccine.

H Käyhty.   

Abstract

Passive hemagglutination (HA), a bactericidal activity test (BCA), and radioimmunoassay (RIA) were compared in measuring serum antibodies before and after group A meningococcal capsular polysaccharide vaccination of servicemen. The three methods were found satisfactory in demonstrating a response to vaccination in this age group. Of the postimmunization sera, 5% remained without HA and 1% remained without BCA activity; 1% of the postimmunization sera had less than 2 micrograms of antibody per ml as measured by RIA. Approximately 60% of the serum pairs showed a greater than or equal to 32-fold rise in HA titer, a greater than or equal 25-fold rise in BCA titer, or a greater than or equal to 4-fold rise in antibody concentration by RIA. A difference in response to two different vaccine lots was seen with RIA and BCA. Although the calculated correlation between the three methods was good, some individual sera gave discrepant results. These could be shown to be due mainly to one of the following factors: low HA titer was due to lack of the immunoglobulin M and A classes of antibodies, low BCA titer was due to the blocking effect of high immunoglobulin A content, and high BCA titer was due to antibodies directed to bacterial components other than the capsular polysaccharide.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6785306      PMCID: PMC273563          DOI: 10.1128/jcm.12.2.256-263.1980

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping.

Authors:  R Gold; J L Winklehake; R S Mars; M S Artenstein
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

2.  Prevention of meningococcal disease by group C polysaccharide vaccine.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; H Schneider; C Harkins
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

3.  Serologic studies of meningococcal infection and polysaccharide vaccination.

Authors:  M S Artenstein; B L Brandt; E C Tramont; W C Branche; H D Fleet; R L Cohen
Journal:  J Infect Dis       Date:  1971-09       Impact factor: 5.226

4.  The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man.

Authors:  R B Roberts
Journal:  J Exp Med       Date:  1970-03-01       Impact factor: 14.307

5.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

6.  Quantitative determination of the human immune response to immunization with meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; R Triau; K J Sparks
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

7.  Human immunity to the meningococcus. II. Development of natural immunity.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

8.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  7 in total

1.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 2.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

3.  Comparison of radioimmunoassay and enzyme-linked immunosorbent assay in measurement of antibodies to Neisseria meningitidis group A capsular polysaccharide.

Authors:  E C Beuvery; M H Kayhty; A B Leussink; V Kanhai
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

4.  Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay.

Authors:  G M Carlone; C E Frasch; G R Siber; S Quataert; L L Gheesling; S H Turner; B D Plikaytis; L O Helsel; W E DeWitt; W F Bibb
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

5.  Recognition of serogroup A Neisseria meningitidis serotype antigens by human antisera.

Authors:  R J Sugasawara
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

6.  Spin membrane immunoassay for use in meningococcal serology.

Authors:  A I Vistnes; E Rosenqvist; L O Frøholm
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

Review 7.  Meningococcal disease and the complement system.

Authors:  Lisa A Lewis; Sanjay Ram
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.